Correlation Between Zoetis and Inhibikase Therapeutics

Can any of the company-specific risk be diversified away by investing in both Zoetis and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zoetis and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zoetis Inc and Inhibikase Therapeutics, you can compare the effects of market volatilities on Zoetis and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zoetis with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zoetis and Inhibikase Therapeutics.

Diversification Opportunities for Zoetis and Inhibikase Therapeutics

-0.75

Correlation Coefficient

Zoetis  Inhibikase Therapeutics

Pay attention - limited upside

The 3 months correlation between Zoetis and Inhibikase is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Zoetis Inc and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Zoetis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zoetis Inc are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Zoetis i.e., Zoetis and Inhibikase Therapeutics go up and down completely randomly.

Pair Corralation between Zoetis and Inhibikase Therapeutics

Considering the 90-day investment horizon Zoetis is expected to generate 29.32 times less return on investment than Inhibikase Therapeutics. But when comparing it to its historical volatility, Zoetis Inc is 4.35 times less risky than Inhibikase Therapeutics. It trades about 0.0 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  367.00  in Inhibikase Therapeutics on August 31, 2024 and sell it today you would lose (94.00) from holding Inhibikase Therapeutics or give up 25.61% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Zoetis Inc  vs.  Inhibikase Therapeutics

Zoetis Inc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zoetis Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Zoetis is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Inhibikase Therapeutics

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Zoetis and Inhibikase Therapeutics

The main advantage of trading using opposite Zoetis and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zoetis position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.

The idea behind Zoetis Inc and Inhibikase Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.